Hereditary Cancer Genetic Testing
personalized cancer risk assessment
Hereditary cancer genetic testing evaluates inherited gene variants associated with increased cancer risk. These variants can influence the likelihood of developing certain cancers and inform personalized screening and prevention strategies.
At CMoC, this testing helps patients understand inherited risk and make informed, proactive decisions about long-term health.
What This Testing Provides
Hereditary cancer genetic testing helps clinicians:
Stratify individual cancer risk
Recommend earlier or more frequent screening
Identify targeted prevention strategies
Support informed family risk counseling
Panels assess genes associated with cancers such as breast, ovarian, colorectal, pancreatic, prostate, and others.
Important Clarification
This testing assesses inherited cancer risk.
It does not detect active cancer.
Testing Options for Hereditary Cancer Risk
CMoC offers multiple hereditary cancer genetic testing options to match different clinical needs, family histories, and levels of desired insight. These tests analyze inherited gene variants associated with an increased risk of cancers such as breast, ovarian, colorectal, pancreatic, prostate, and others.
Testing options range from targeted hereditary cancer panels to expanded multi-gene panels, allowing clinicians to tailor testing based on personal and family history, prior testing, and specific risk concerns. Some options focus on the most well-established cancer-associated genes, while others evaluate a broader set of genes to provide more comprehensive risk assessment.
For patients seeking the most extensive genetic insight, hereditary cancer risk assessment may also be incorporated into whole genome sequencing, which evaluates cancer risk alongside other inherited and polygenic health factors.
Your clinician will help determine which testing approach is most appropriate—ensuring results are clinically meaningful, actionable, and aligned with your long-term care plan.
MyRisk by Myraid - $249 or billed to insurance
MyRisk is a comprehensive hereditary cancer panel that analyzes 48 genes associated with elevated risk for breast, ovarian, colorectal, and other cancers.
It combines next-generation sequencing with Myriad’s validated risk assessment models to guide clinical decision-making for screening, prevention, and chemoprevention.
Results also include Myriad’s RiskScore, which integrates genetic and clinical factors to personalize cancer risk beyond family history alone.
Empower by Natera - $249 or billed to insurance
Empower is a hereditary cancer test that evaluates up to 81 genes linked to a broad spectrum of hereditary cancers, including breast, ovarian, pancreatic, and prostate.
It uses advanced sequencing and bioinformatics to provide accurate, clinically actionable results, with built-in support for both patient counseling and provider interpretation.
Empower testing can be customized by panel type and includes reflex options for additional gene analysis based on clinical indication.
MyOme - $575 base/$775 plus
MyOme performs whole genome sequencing to deliver a complete picture of an individual’s genetic makeup, identifying both rare pathogenic variants and polygenic risk scores across multiple disease categories.
Take a Proactive Step Toward Cancer Prevention
Hereditary cancer genetic testing can inform earlier screening and targeted prevention strategies. Our team will guide you through testing options and help you understand what your results mean for your care.